Pricing Log in Create free account
Saturday 17 October 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.

790.74 5.60 −0.70%
Market cap
$82.0B
P/E
18.9×
Fwd P/E
16.5×
Dividend yield
0.47%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Regeneron Pharmaceuticals, Inc. (REGN) Revenue growth

Alert me on Revenue growth

Regeneron Pharmaceuticals, Inc.'s revenue growth over the twelve months to 30 June 2026 was 9.29%, up 8.3 percentage points from fiscal 2025 (0.99%). Over the past ten years it has ranged from −24.3% (fiscal 2022) to 89.1% (fiscal 2021); the current reading is higher than 27% of that period. That is above the Biotechnology industry median of 6.02% and above the Healthcare sector median of 8.27%.

Revenue growth, annual

Embed this chart

Annual newest first

Period Revenue growth Change (points)
FY2025 0.99% (7.28)
FY2024 8.27% 0.51
FY2023 7.76% 32.02
FY2022 −24.3% (113.40)
FY2021 89.1% 59.56
FY2020 29.6% 2.14
FY2019 27.4% 39.81
FY2018 −12.4% (33.19)
FY2017 20.8% 2.38
FY2016 18.4% (27.11)

Quarterly newest first

Period Revenue growth Change (points)
Jun 2026 16.7% (2.31)
Mar 2026 19.0% 16.53
Dec 2025 2.51% 1.61
Sep 2025 0.90% (2.72)
42 more quarters

Against its own ten years

Low −24.3% High 89.1%
Ten-year median 18.4%
Current reading's percentile 27

Revenue growth against peers

Company Revenue growth
ALNY Alnylam Pharmaceuticals, Inc. compare 95.1%
ARGX argenex SE compare 70.6%
ONC BeOne Medicines Ltd. - Sponsored ADR compare 34.4%
VRTX Vertex Pharmaceuticals Incorporated compare 10.2%
RPRX Royalty Pharma PLC compare 10.0%
REGN Regeneron Pharmaceuticals, Inc. 9.29%
RVMD Revolution Medicines, Inc. compare −8.81%
MRNA Moderna, Inc. compare −27.6%
ROIV Roivant Sciences Ltd. compare −67.6%
Biotechnology industry median 6.02%
Healthcare sector median 8.27%
Market median 7.41%

What Revenue growth is

Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.

(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|

The full definition of Revenue growth →

More on REGN